Does the media prefer ROIV or LEGN?

In the previous week, Legend Biotech had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 6 mentions for Legend Biotech and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.18 beat Legend Biotech's score of 0.62 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VTRS or LEGN more profitable?

Viatris has a net margin of -2.04% compared to Legend Biotech's net margin of -21.98%. Viatris' return on equity of 19.04% beat Legend Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Legend Biotech -21.98% -24.92% -14.87%

Is LEGN or MRNA more profitable?

Legend Biotech has a net margin of -21.98% compared to Moderna's net margin of -143.55%. Legend Biotech's return on equity of -24.92% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -21.98% -24.92% -14.87% Moderna -143.55% -26.64% -19.32%

Does the media favor LEGN or MRNA?

In the previous week, Moderna had 3 more articles in the media than Legend Biotech. MarketBeat recorded 9 mentions for Moderna and 6 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.62 beat Moderna's score of 0.44 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has higher valuation and earnings, LEGN or GMAB?

Genmab A/S has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Legend Biotech $1.03B 4.61 -$296.80M -$0.68 N/A Genmab A/S $3.72B 4.27 $963M $1.32 19.28

Is LEGN or GMAB more profitable?

Genmab A/S has a net margin of 21.05% compared to Legend Biotech's net margin of -21.98%. Genmab A/S's return on equity of 15.34% beat Legend Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -21.98% -24.92% -14.87% Genmab A/S 21.05% 15.34% 8.94%

Does the media favor LEGN or GMAB?

In the previous week, Legend Biotech had 2 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Legend Biotech and 4 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.72 beat Legend Biotech's score of 0.62 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ASND or LEGN?

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Legend Biotech. MarketBeat recorded 8 mentions for Ascendis Pharma A/S and 6 mentions for Legend Biotech. Ascendis Pharma A/S's average media sentiment score of 1.31 beat Legend Biotech's score of 0.62 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Legend Biotech (LEGN) Competitors

$25.51 -1.65 (-6.08%)

Closing price 04:00 PM Eastern

Extended Trading

$25.48 -0.03 (-0.13%)

As of 07:56 PM Eastern

Compare

LEGN vs. ROIV, VTRS, MRNA, GMAB, and ASND

Should you buy Legend Biotech stock or one of its competitors? MarketBeat compares Legend Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Legend Biotech include Roivant Sciences (ROIV), Viatris (VTRS), Moderna (MRNA), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

How does Legend Biotech compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Legend Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,533.12	-$299.77M	-$0.60	N/A
Legend Biotech	$1.03B	4.61	-$296.80M	-$0.68	N/A

Roivant Sciences presently has a consensus target price of $33.59, suggesting a potential upside of 15.47%. Legend Biotech has a consensus target price of $59.15, suggesting a potential upside of 131.88%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Roivant Sciences has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Legend Biotech had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 6 mentions for Legend Biotech and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.18 beat Legend Biotech's score of 0.62 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Legend Biotech has a net margin of -21.98% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Legend Biotech	-21.98%	-24.92%	-14.87%

Summary

Legend Biotech beats Roivant Sciences on 8 of the 15 factors compared between the two stocks.

How does Legend Biotech compare to Viatris?

Viatris (NASDAQ:VTRS) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

In the previous week, Legend Biotech had 5 more articles in the media than Viatris. MarketBeat recorded 6 mentions for Legend Biotech and 1 mentions for Viatris. Viatris' average media sentiment score of 1.89 beat Legend Biotech's score of 0.62 indicating that Viatris is being referred to more favorably in the media.

Company	Overall Sentiment
Viatris	Very Positive
Legend Biotech	Positive

79.9% of Viatris shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Viatris currently has a consensus target price of $16.43, indicating a potential upside of 3.91%. Legend Biotech has a consensus target price of $59.15, indicating a potential upside of 131.88%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Viatris has a net margin of -2.04% compared to Legend Biotech's net margin of -21.98%. Viatris' return on equity of 19.04% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Legend Biotech	-21.98%	-24.92%	-14.87%

Viatris has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Legend Biotech has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Legend Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.29	-$3.51B	-$0.26	N/A
Legend Biotech	$1.03B	4.61	-$296.80M	-$0.68	N/A

Summary

Viatris beats Legend Biotech on 9 of the 15 factors compared between the two stocks.

How does Legend Biotech compare to Moderna?

Legend Biotech (NASDAQ:LEGN) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Legend Biotech has a net margin of -21.98% compared to Moderna's net margin of -143.55%. Legend Biotech's return on equity of -24.92% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Moderna	-143.55%	-26.64%	-19.32%

Legend Biotech presently has a consensus price target of $59.15, suggesting a potential upside of 131.88%. Moderna has a consensus price target of $35.73, suggesting a potential downside of 22.42%. Given Legend Biotech's stronger consensus rating and higher probable upside, research analysts plainly believe Legend Biotech is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Legend Biotech has higher earnings, but lower revenue than Moderna. Legend Biotech is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	4.61	-$296.80M	-$0.68	N/A
Moderna	$1.94B	9.40	-$2.82B	-$8.15	N/A

In the previous week, Moderna had 3 more articles in the media than Legend Biotech. MarketBeat recorded 9 mentions for Moderna and 6 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.62 beat Moderna's score of 0.44 indicating that Legend Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Legend Biotech has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Legend Biotech beats Moderna on 9 of the 15 factors compared between the two stocks.

How does Legend Biotech compare to Genmab A/S?

Legend Biotech (NASDAQ:LEGN) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

In the previous week, Legend Biotech had 2 more articles in the media than Genmab A/S. MarketBeat recorded 6 mentions for Legend Biotech and 4 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.72 beat Legend Biotech's score of 0.62 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Legend Biotech has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Legend Biotech presently has a consensus price target of $59.15, indicating a potential upside of 131.88%. Genmab A/S has a consensus price target of $37.93, indicating a potential upside of 49.03%. Given Legend Biotech's higher possible upside, analysts clearly believe Legend Biotech is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Genmab A/S has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	4.61	-$296.80M	-$0.68	N/A
Genmab A/S	$3.72B	4.27	$963M	$1.32	19.28

Genmab A/S has a net margin of 21.05% compared to Legend Biotech's net margin of -21.98%. Genmab A/S's return on equity of 15.34% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Genmab A/S	21.05%	15.34%	8.94%

Summary

Genmab A/S beats Legend Biotech on 11 of the 16 factors compared between the two stocks.

How does Legend Biotech compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Ascendis Pharma A/S has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Ascendis Pharma A/S presently has a consensus target price of $295.39, suggesting a potential upside of 34.99%. Legend Biotech has a consensus target price of $59.15, suggesting a potential upside of 131.88%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Ascendis Pharma A/S has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$865.78M	15.77	-$258M	$8.67	25.24
Legend Biotech	$1.03B	4.61	-$296.80M	-$0.68	N/A

70.9% of Legend Biotech shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Ascendis Pharma A/S has a net margin of 57.87% compared to Legend Biotech's net margin of -21.98%. Ascendis Pharma A/S's return on equity of 0.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Legend Biotech	-21.98%	-24.92%	-14.87%

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Legend Biotech. MarketBeat recorded 8 mentions for Ascendis Pharma A/S and 6 mentions for Legend Biotech. Ascendis Pharma A/S's average media sentiment score of 1.31 beat Legend Biotech's score of 0.62 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Legend Biotech on 13 of the 16 factors compared between the two stocks.

Get Legend Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEGN vs. The Competition

Export

Metric	Legend Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.04B	$3.32B	$6.31B	$12.59B
Dividend Yield	N/A	2.28%	2.68%	5.22%
P/E Ratio	N/A	18.07	21.13	26.63
Price / Sales	4.61	326.58	546.66	114.76
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	4.70	6.84	9.95	6.88
Net Income	-$296.80M	$24.15M	$3.56B	$336.73M
7 Day Performance	-13.14%	1.93%	2.12%	4.19%
1 Month Performance	N/A	N/A	N/A	-0.08%
1 Year Performance	-11.27%	62.98%	36.32%	40.26%

Legend Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEGN Legend Biotech	4.2292 of 5 stars	$25.51 -6.1%	$59.15 +131.9%	-5.5%	$5.04B	$1.03B	N/A	2,965	News Coverage Analyst Forecast
ROIV Roivant Sciences	2.7585 of 5 stars	$29.96 flat	$33.05 +10.3%	+173.1%	$21.44B	$8.26M	N/A	860	Positive News Gap Down
VTRS Viatris	3.1443 of 5 stars	$16.65 flat	$16.43 -1.3%	+85.6%	$19.39B	$14.30B	N/A	30,000
MRNA Moderna	1.5061 of 5 stars	$46.88 flat	$35.73 -23.8%	+77.7%	$18.60B	$1.94B	N/A	4,700
GMAB Genmab A/S	4.0349 of 5 stars	$26.87 flat	$39.07 +45.4%	+25.8%	$16.75B	$3.72B	20.36	3,029

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEGN) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Legend Biotech (LEGN) Competitors

LEGN vs. ROIV, VTRS, MRNA, GMAB, and ASND

How does Legend Biotech compare to Roivant Sciences?

Summary

How does Legend Biotech compare to Viatris?

Summary

How does Legend Biotech compare to Moderna?

Summary

How does Legend Biotech compare to Genmab A/S?

Summary

How does Legend Biotech compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Legend Biotech (LEGN) Competitors

LEGN vs. ROIV, VTRS, MRNA, GMAB, and ASND

How does Legend Biotech compare to Roivant Sciences?

Which has higher earnings & valuation, ROIV or LEGN?

Do analysts prefer ROIV or LEGN?

Which has more volatility and risk, ROIV or LEGN?

Do institutionals and insiders hold more shares of ROIV or LEGN?

Does the media prefer ROIV or LEGN?

Is ROIV or LEGN more profitable?

Summary

How does Legend Biotech compare to Viatris?

Does the media refer more to VTRS or LEGN?

Do institutionals and insiders hold more shares of VTRS or LEGN?

Do analysts rate VTRS or LEGN?

Is VTRS or LEGN more profitable?

Which has more volatility and risk, VTRS or LEGN?

Which has stronger valuation & earnings, VTRS or LEGN?

Summary

How does Legend Biotech compare to Moderna?

Is LEGN or MRNA more profitable?

Do analysts prefer LEGN or MRNA?

Which has higher earnings and valuation, LEGN or MRNA?

Does the media favor LEGN or MRNA?

Which has more volatility and risk, LEGN or MRNA?

Do insiders & institutionals have more ownership in LEGN or MRNA?

Summary

How does Legend Biotech compare to Genmab A/S?

Does the media favor LEGN or GMAB?

Which has more risk and volatility, LEGN or GMAB?

Do institutionals and insiders hold more shares of LEGN or GMAB?

Do analysts recommend LEGN or GMAB?

Which has higher valuation and earnings, LEGN or GMAB?

Is LEGN or GMAB more profitable?

Summary

How does Legend Biotech compare to Ascendis Pharma A/S?

Which has more risk and volatility, ASND or LEGN?

Do analysts prefer ASND or LEGN?

Which has stronger earnings and valuation, ASND or LEGN?

Do insiders and institutionals hold more shares of ASND or LEGN?

Is ASND or LEGN more profitable?

Does the media favor ASND or LEGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEGN vs. The Competition

Legend Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools